Investigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Model

Basit Öğe Kaydı
dc.authoridDokuyucu, Recep/0000-0001-7881-8871
dc.authoridKarahan, Serkan/0000-0002-1203-7615
dc.authoridDokuyucu, Recep/0000-0001-6837-3477
dc.contributor.authorKarateke, Atilla
dc.contributor.authorDokuyucu, Recep
dc.contributor.authorDogan, Hatice
dc.contributor.authorOzgur, Tumay
dc.contributor.authorTas, Zeynel Abidin
dc.contributor.authorTutuk, Okan
dc.contributor.authorAgturk, Gokhan
dc.date.accessioned2024-09-18T20:54:21Z
dc.date.available2024-09-18T20:54:21Z
dc.date.issued2018
dc.departmentHatay Mustafa Kemal Üniversitesien_US
dc.description.abstractObjective: Polycystic ovary syndrome (PCOS) is a serious endocrine disorder. In the present study, we investigated the therapeutic effects of erdosteine in letrozole-induced PCOS in rats. Methods: Thirty-two Wistar albino female rats were grouped as control group (C), PCOS group (PCOS), PCOS-metformin group (PCOS+MET), and PCOS-erdosteine group (PCOS+Erd). PCOS was induced by administering letrozole; such rats presented with sex hormone disorder, abnormal estrous cycles determined by daily vaginal smear, large cystic follicles, and increasing fasting insulin levels. After induction of PCOS, metformin (500 mg/kg/day) and erdosteine (100 mg/kg/day) were given orally to the treatment groups for 30 days. Serum concentrations of glucose, total cholesterol, low-and high-density lipoprotein, triglyceride, as well as the total oxidant and antioxidant status, oxidative stress index, circulating estrone (E1), estradiol (E2), testosterone, and androstenedione were evaluated. The ovaries were graded histologically. Results: Weights of ovarian tissues (p < 0.05) and the number of atretic follicles (p < 0.001) and cystic follicles (p < 0.01) decreased in the PCOS+Erd group; the corpus luteum number was significantly higher in the PCOS+Erd group (p < 0.01) as compared with the PCOS group. Lipid parameters (total-C, LDL-C, and TG), E1 (estrone), E1/E2 ratio, testosterone, and androstenedione significantly decreased, while HDL-C and E2 (estradiol) significantly increased in the PCOS+Erd group as compared with the PCOS group. Moreover glucose, insulin, and HOMA-IR were reduced with treatment of erdosteine (p > 0.05, p < 0.001, and p < 0.001, respectively). Conclusion: It is suggested that erdosteine may be used in the treatment of PCOS as an alternative to metformin. It appears that our findings might be supported by clinical and molecular studies. (c) 2018 The Author(s) Published by S. Karger AG, Baselen_US
dc.identifier.doi10.1159/000494300
dc.identifier.endpage522en_US
dc.identifier.issn1011-7571
dc.identifier.issn1423-0151
dc.identifier.issue6en_US
dc.identifier.pmid30293079en_US
dc.identifier.scopus2-s2.0-85062405833en_US
dc.identifier.scopusqualityQ1en_US
dc.identifier.startpage515en_US
dc.identifier.urihttps://doi.org/10.1159/000494300
dc.identifier.urihttps://hdl.handle.net/20.500.12483/11761
dc.identifier.volume27en_US
dc.identifier.wosWOS:000460975100003en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherKargeren_US
dc.relation.ispartofMedical Principles and Practiceen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectPolycystic ovary syndromeen_US
dc.subjectMetforminen_US
dc.subjectErdosteineen_US
dc.subjectLetrozoleen_US
dc.titleInvestigation of Therapeutic Effects of Erdosteine on Polycystic Ovary Syndrome in a Rat Modelen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
Tam Metin / Full Text
Boyut:
352.01 KB
Biçim:
Adobe Portable Document Format
İndir

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu